84 related articles for article (PubMed ID: 11146896)
1. Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment.
Raffayová H; Rovenský J; Mális F
Int J Clin Pharmacol Res; 2000; 20(1-2):1-11. PubMed ID: 11146896
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
3. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.
Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Lodi L; Bisighini G; Portioli I
J Rheumatol; 1992 Jan; 19(1):74-9. PubMed ID: 1556703
[TBL] [Abstract][Full Text] [Related]
4. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
6. Psoriatic arthritis treated with cyclosporin A.
Kokelj F; Lavaroni G; Stinco G
Allerg Immunol (Paris); 1992 Dec; 24(10):393-4. PubMed ID: 1288546
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
Kivitz AJ; Espinoza LR; Sherrer YR; Liu-Dumaw M; West CR
Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
Gül U; Gönül M; Kiliç A; Erdem R; Cakmak SK; Gündüz H
Clin Ther; 2006 Feb; 28(2):251-4. PubMed ID: 16678646
[TBL] [Abstract][Full Text] [Related]
10. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
12. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
[TBL] [Abstract][Full Text] [Related]
13. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
Bongartz T; Coras B; Vogt T; Schölmerich J; Müller-Ladner U
Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756
[TBL] [Abstract][Full Text] [Related]
14. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
15. Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis.
Swanson DL; Barnes SA; Mengden Koon SJ; el-Azhary RA
Int J Dermatol; 2007 Feb; 46(2):157-9. PubMed ID: 17269967
[TBL] [Abstract][Full Text] [Related]
16. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
[TBL] [Abstract][Full Text] [Related]
17. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
Cauza E; Cauza K; Hanusch-Enserer U; Etemad M; Dunky A; Kostner K
Wien Klin Wochenschr; 2002 Dec; 114(23-24):1004-7. PubMed ID: 12635469
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
Vena GA; Cassano N; Colombo D; Peruzzi E; Pigatto P;
J Am Acad Dermatol; 2006 Oct; 55(4):705-9. PubMed ID: 17010756
[TBL] [Abstract][Full Text] [Related]
19. Short-term "cyclosporin A" therapy for psoriatic arthritis.
Riccieri V; Sili Scavalli A; Spadaro A; Bracci M; Taccari E; Zoppini A
Acta Derm Venereol Suppl (Stockh); 1994; 186():94-5. PubMed ID: 8073853
[No Abstract] [Full Text] [Related]
20. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
